ASCO: Phase III QUAZAR AML-001 trial
Abstract No : 7530
Abstract Type : Poster Discussion Session
Indication : Acute Myeloid Leukemia
Intervention : CC-486
Company : BMS
Technology : Small molecule
CC-486 is safe and well-tolerated as maintenance therapy in elderly patients ($75 years) with acute myeloid leukemia (AML) in first remission following induction chemotherapy: Results from the phase III QUAZAR AML-001 trial.
ASCO: KEYNOTE-189 study
Abstract No : 9582
Abstract Type : Poster Session
Indication : Nonsquamous NSCLC
Intervention : Pemetrexed-platinum chemotherapy (chemo) with or without pembrolizumab (pembro)
Company : Merck Sharp & Dohme Corp.
Technology : Monoclonal antibody
Final data of KEYNOTE-189 study in patients with newly diagnosed metastatic nonsquamous NSCLC
ASCO: Initial KarMMa results
Abstract No : 8503
Abstract Type : Oral Abstract Session
Indication : Multiple Myeloma
Intervention : Idecabtagene vicleucel
Company : Bristol-Myers Squibb and bluebird bio.
Technology : CAR T Cell Therapy
Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results
Anti-cd47 Antibody Magrolimab Combined With Azacitidine
Abstract No : 7507
Abstract Type : Poster Discussion Session
Indication : MDS/AML
Intervention : Magrolimab
Company : Forty Seven, Inc
Technology : Monoclonal antibody
Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in MDS and AML patients: Phase Ib results
